Search Results

There are 6865 results for: content related to: Intranasal naloxone for the treatment of suspected heroin overdose

  1. REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade

    Addiction Biology

    Volume 12, Issue 3-4, September 2007, Pages: 227–462, Thomas M. Tzschentke

    Version of Record online : 30 JUL 2007, DOI: 10.1111/j.1369-1600.2007.00070.x

  2. Neural correlates of the motivational and somatic components of naloxone-precipitated morphine withdrawal

    European Journal of Neuroscience

    Volume 16, Issue 7, October 2002, Pages: 1377–1389, François Frenois, Martine Cador, Stéphanie Caillé, Luis Stinus and Catherine Le Moine

    Version of Record online : 29 OCT 2002, DOI: 10.1046/j.1460-9568.2002.02187.x

  3. Naloxone—does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose

    Addiction

    Volume 110, Issue 10, October 2015, Pages: 1644–1652, Joanne Neale and John Strang

    Version of Record online : 30 JUL 2015, DOI: 10.1111/add.13027

  4. You have free access to this content
    Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?

    Addiction

    Volume 111, Issue 4, April 2016, Pages: 574–582, John Strang, Rebecca McDonald, Basak Tas and Ed Day

    Version of Record online : 3 FEB 2016, DOI: 10.1111/add.13209

  5. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4

    British Journal of Pharmacology

    Volume 173, Issue 5, March 2016, Pages: 856–869, X Wang, Y Zhang, Y Peng, M R Hutchinson, K C Rice, H Yin and L R Watkins

    Version of Record online : 4 FEB 2016, DOI: 10.1111/bph.13394

  6. You have full text access to this OnlineOpen article
    Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study

    Pain Practice

    Volume 16, Issue 5, June 2016, Pages: 580–599, Ralf Baron, Rudolf Likar, Emilio Martin-Mola, Francisco J. Blanco, Lieven Kennes, Matthias Müller, Dietmar Falke and Ilona Steigerwald

    Version of Record online : 12 JUN 2015, DOI: 10.1111/papr.12308

  7. Phosphodiesterase inhibition by naloxone augments the inotropic actions of β-adrenergic stimulation

    Acta Anaesthesiologica Scandinavica

    Volume 53, Issue 8, September 2009, Pages: 1043–1051, W. K. PARK, C. H. CHANG, J. E. CHAE, M. H. KIM, Y. L. CHO and D. S. AHN

    Version of Record online : 30 JUN 2009, DOI: 10.1111/j.1399-6576.2009.02023.x

  8. You have full text access to this OnlineOpen article
    Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial

    Pain Practice

    Volume 16, Issue 5, June 2016, Pages: 600–619, Ralf Baron, Jan-Peter Jansen, Andreas Binder, Manuel Pombo-Suarez, Lieven Kennes, Matthias Müller, Dietmar Falke and Ilona Steigerwald

    Version of Record online : 11 NOV 2015, DOI: 10.1111/papr.12361

  9. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond

    Drug and Alcohol Review

    Volume 34, Issue 4, July 2015, Pages: 404–411, Simon Lenton, Paul Dietze, Anna Olsen, Nicole Wiggins, David McDonald and Carrie Fowlie

    Version of Record online : 1 OCT 2014, DOI: 10.1111/dar.12198

  10. Take-home naloxone to reduce heroin death

    Addiction

    Volume 100, Issue 12, December 2005, Pages: 1823–1831, Catherine T. Baca and Kenneth J. Grant

    Version of Record online : 23 NOV 2005, DOI: 10.1111/j.1360-0443.2005.01259.x

  11. You have free access to this content
    Naloxone reversal of an overdose of a novel, long-acting transdermal fentanyl solution in laboratory Beagles

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 35, Issue s2, August 2012, Pages: 45–51, K. J. FREISE, G. C. NEWBOUND, C. TUDAN and T. P. CLARK

    Version of Record online : 25 JUN 2012, DOI: 10.1111/j.1365-2885.2012.01409.x

  12. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal

    Addiction

    Suzanne Nielsen, Nadia Menon, Sarah Larney, Michael Farrell and Louisa Degenhardt

    Version of Record online : 16 AUG 2016, DOI: 10.1111/add.13517

  13. Morphine withdrawal increases intrinsic excitability of oxytocin neurons in morphine-dependent rats

    European Journal of Neuroscience

    Volume 21, Issue 2, January 2005, Pages: 501–512, Colin H. Brown, Javier E. Stern, Keshia L. M. Jackson, Philip M. Bull, Gareth Leng and John A. Russell

    Version of Record online : 19 JAN 2005, DOI: 10.1111/j.1460-9568.2005.03885.x

  14. Mu-opioid antagonists for opioid-induced bowel dysfunction

    Intervention Review

    The Cochrane Library

    Ewan D McNicol, David Boyce, Roman Schumann and Daniel B Carr

    Published Online : 23 APR 2008, DOI: 10.1002/14651858.CD006332.pub2

  15. You have free access to this content
    Protein kinase C phosphorylates the cAMP response element binding protein in the hypothalamic paraventricular nucleus during morphine withdrawal

    British Journal of Pharmacology

    Volume 163, Issue 4, June 2011, Pages: 857–875, F Martín, L Mora, ML Laorden and MV Milanés

    Version of Record online : 26 MAY 2011, DOI: 10.1111/j.1476-5381.2011.01287.x

  16. Naloxone increases maturation rate and ratio of inner cell mass to total cells in blastocysts in pigs

    Animal Science Journal

    Volume 84, Issue 12, December 2013, Pages: 765–773, Thanh Quang Dang-Nguyen, Nguyen Viet Linh, Rosa Minoia, Masahiro Kaneda, Tamas Somfai, Seiki Haraguchi, Satoshi Akagi, Kazuhiro Kikuchi, Michiko Nakai, Atsushi Tajima and Takashi Nagai

    Version of Record online : 3 MAY 2013, DOI: 10.1111/asj.12071

  17. The acceptability of combined methadone-naloxone treatment: Consumer and provider views on the potential utility of methadone-naloxone

    Drug and Alcohol Review

    Volume 29, Issue 2, March 2010, Pages: 138–143, JAMES SHEARER, KRISTIE MAMMEN and JAMES BELL

    Version of Record online : 5 OCT 2009, DOI: 10.1111/j.1465-3362.2009.00118.x

  18. You have free access to this content
    A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine

    FEMS Immunology & Medical Microbiology

    Volume 61, Issue 1, February 2011, Pages: 54–62, Nima Hosseini Jazani, Mohammad Sohrabpour, Ebrahim Mazloomi and Shahram Shahabi

    Version of Record online : 5 NOV 2010, DOI: 10.1111/j.1574-695X.2010.00747.x

  19. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans

    Addiction

    Volume 98, Issue 4, April 2003, Pages: 427–439, Sharon L. Walsh, Eric C. Strain and George E. Bigelow

    Version of Record online : 25 MAR 2003, DOI: 10.1046/j.1360-0443.2003.00372.x

  20. You have free access to this content
    Development and implementation of intranasal naloxone opioid overdose response protocol at a homeless health clinic

    Journal of the American Association of Nurse Practitioners

    Volume 28, Issue 1, January 2016, Pages: 11–18, Chin Hwa Y. Dahlem, Molly J. Horstman and Brent C. Williams

    Version of Record online : 26 MAR 2015, DOI: 10.1002/2327-6924.12249